Over 50 million people worldwide suffering from dementia-related disorders.

Neurocognitive Disorders

Neurocognitive disorders, including conditions like dementia and Alzheimer's disease, are characterized by a significant decline in cognitive function. Recent research suggests that psychedelics may offer potential therapeutic benefits by promoting neuronal connectivity and enhancing psychological recovery in these patients.

What is Neurocognitive Disorders?

Neurocognitive disorders are a group of conditions that result in a decline of mental functions attributable to causes other than psychiatric illness. Common examples include dementia, Alzheimer’s disease, and traumatic brain injuries. The pathophysiology often involves neurodegeneration and synaptic loss, leading to cognitive impairments such as memory loss, difficulty with problem-solving, and changes in behaviour or personality.

Symptoms of neurocognitive disorders can vary widely but typically manifest as forgetfulness, confusion, difficulty maintaining attention or learning new information, and impairments in judgment. As the condition progresses, individuals may also experience significant impacts on daily functioning and quality of life.

Current Treatments

Current standard-of-care treatments primarily include cognitive-enhancing medications such as cholinesterase inhibitors for Alzheimer's disease, along with supportive therapies like cognitive rehabilitation and psychosocial interventions.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Neurocognitive Disorders.

Compound	Magnitude	Evidence	Consistency
Psilocybin Clinical trials have shown psilocybin's benefits in improving mental health outcomes and cognitive functions in case studies related to neurocognitive impairments.	Medium	Moderate	Consistent
LSD Preliminary studies suggest potential benefits, but more research is needed to confirm consistent effects on neurocognitive disorders.	Medium	Moderate	Inconsistent
MDMA Promising results from trials indicate MDMA's capacity to alleviate symptoms of trauma, which can be beneficial to cognitive function recovery post-injury.	Medium	Moderate	Consistent

Psilocybin and Neurocognitive Disorders

Psilocybin, a naturally occurring psychedelic compound, has been shown to promote neuroplasticity and enhance mood. Its ability to facilitate emotional processing might aid individuals suffering from mood-related symptoms associated with neurocognitive disorders. The restoration of cognitive functions may stem from its action on serotonin receptors, ultimately leading to improved neuronal connectivity.

View full Psilocybin profile →

LSD and Neurocognitive Disorders

LSD acts as a non-specific agonist of serotonin receptors, which may result in enhanced synaptic connections and neuroplasticity. Though research is in preliminary phases regarding its efficacy for neurocognitive disorders, the potential for LSD to foster new learning pathways could be a valuable asset in cognitive rehabilitation strategies for patients.

View full LSD profile →

Key Insights

1
Psychedelics may enhance neuroplasticity, which is essential for cognitive recovery in neurodegenerative conditions.
2
Research indicates that psychedelics can improve mood and reduce anxiety, which are significant concerns for patients with neurocognitive disorders.
3
Preliminary studies show that psychedelics may facilitate communication between different brain regions, potentially restoring disrupted neuronal connectivity.

Industrial Landscape

Key stakeholders in the research of neurocognitive disorders include academic institutions, pharmaceutical companies, and non-profit organisations dedicated to brain health, such as the Alzheimer's Association and MAPS (Multidisciplinary Association for Psychedelic Studies).

Quick Indicators

PrevalenceOver 50 million people worldwide suffering from dementia-related disorders.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Neurocognitive Disorders as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.